Isis Pharmaceuticals launched a pivotal phase 3 trial of ISIS-SMNrx, an experimental treatment for spinal muscular atrophy, according to a Reuters report.
Spinal muscular atrophy is a rare, genetic disease that causes severe muscle atrophy and weakness in infants and children. Ongoing mid-stage studies are showing that the drug increases muscle function in those suffering from the disease.
Isis currently enrolling infants with the disease in a phase 3 study, and it plans to begin a second phase 3 study of children with SMA later this year, according to the report.
More articles on devices:
37 spine, orthopedic devices receive FDA 510(k) clearance in September
Nevro files IPO — 6 things to know
BD buys CareFusion for $12.2B: 8 things to know